ERRATUM - Pre-treatment of the beta3-adrenergic receptor agonist BRL37344 reduces in vivo myocardial ischemia/reperfusion injury by improving AMPK and SIRT1 activity and by suppressing mTOR and p70S6K signaling pathways

Abstract

Article: “Pre-treatment of the beta3-adrenergic receptor agonist BRL37344 reduces in vivo myocardial ischemia/reperfusion injury by improving AMPK and SIRT1 activity and by suppressing mTOR and p70S6K signaling pathways”, Authors: Dilan AŞKIN ÖZEK, Elif ONAT, Kazım ŞAHİN, Mehmet TUZCU, Merve Yılmaz BOZOĞLAN, Engin ŞAHNA, published in the Brazilian Journal of Pharmaceutical Sciences, vol 59: 1–7, 2023. DOI: https://doi.org/10.1590/s2175-97902023e23002.

The authors would like to correct an error identified in Figure 2 of the published article. During the preparation of the figure, an inadvertent error occurred in the assembly of the western blot band images. Specifically, incorrect band images were placed in the panels for SIRT1 and p70S6K during figure construction. Importantly, the quantitative graphs presented in Figure 2 were generated from densitometric analyses of the correct original western blot data. The original raw data and unprocessed band images, including files with verifiable original creation dates, have previously been provided to the editorial office for transparency. Therefore, the graphical results accurately reflect the underlying experimental findings. This error is limited to the visual placement of representative band images and does not affect the quantitative analyses, scientific results, or the conclusions of the study. The corrected version of Figure 2 is provided below, following the original version. The authors apologize for this error and any inconvenience caused.